Donald Trump's electoral victory has shaken the market, mostly in a good way.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Pfizer presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
PFE's core portfolio and strategic acquisitions continue to deliver decent results, no matter the lumpy sales contribution from Comirnaty and Paxlovid. The company raised their FY2024 core portfolio sales guidance, with the richer adj EPS numbers signaling the management's promising progress in cost and operational optimization. Even so, PFE continues to face massive patent cliff headwinds through 2030, with $31.58B of its annualized FQ3'24 revenues at stake.
One stock yields 6% today. Another has grown its dividend by 460% over the past decade.
Pfizer is trading above its 52-week low but is still a dirt cheap buy.
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
An activist investor has correctly identified a dysfunctional area of the business.
Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street's bearish take on this proven innovator may not be warranted.
Slowly but surely, the company's prospects are looking more attractive.
The pipeline could yield a winner, but so could a few organizational changes.